Effects of zidovudine treatment on heart mRNA expression and mitochondrial DNA copy number associated with alterations in deoxynucleoside triphosphate composition in a neonatal rat model

Jacob W. Snowdin, Chia Heng Hsiung, Daniel G. Kesterson, Vasudeva G. Kamath, Edward E. McKee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The prevention of mother-to-child transmission (MTCT) of HIV is a crucial component in HIV therapy. Nucleoside reverse transcriptase inhibitors (NRTIs), primarily 3'-azido-3'-thymidine (AZT [zidovudine]), have been used to treat both mothers and neonates. While AZT is being replaced with less toxic drugs in treating mothers in MTCT prevention, it is still commonly used to treat neonates. Problems related to mitochondrial toxicity and potential mutagenesis associated with AZT treatment have been reported in treated cohorts. Yet little is known concerning the metabolism and potential toxicity of AZT on embryonic and neonatal tissues, especially considering that the enzymes of nucleoside metabolism change dramatically as many tissues convert from hyperplastic to hypertrophic growth during this period. AZT is known to inhibit thymidine phosphorylation and potentially alter deoxynucleoside triphosphate (dNTP) pools in adults. This study examines the effects of AZT on dNTP pools, mRNA expression of deoxynucleoside/deoxynucleotide metabolic enzymes, and mitochondrial DNA levels in a neonatal rat model. Results show that AZT treatment dramatically altered dNTP pools in the first 7 days of life after birth, which normalized to agematched controls in the second and third weeks. Additionally, AZT treatment dramatically increased the mRNA levels of many enzymes involved in deoxynucleotide synthesis and mitochondrial biogenesis during the first week of life, which normalized to age-matched controls by the third week. These results were correlated with depletion of mitochondrial DNA noted in the second week. Taken together, results demonstrated that AZT treatment has a powerful effect on the deoxynucleotide synthesis pathways that may be associated with toxicity and mutagenesis.

Original languageEnglish (US)
Pages (from-to)6328-6336
Number of pages9
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number10
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Zidovudine
Mitochondrial DNA
Messenger RNA
Mothers
Nucleosides
Mutagenesis
Thymidine
Enzymes
HIV
Newborn Infant
Therapeutics
Reverse Transcriptase Inhibitors
Poisons
Organelle Biogenesis
Phosphorylation
triphosphoric acid
Parturition
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Effects of zidovudine treatment on heart mRNA expression and mitochondrial DNA copy number associated with alterations in deoxynucleoside triphosphate composition in a neonatal rat model. / Snowdin, Jacob W.; Hsiung, Chia Heng; Kesterson, Daniel G.; Kamath, Vasudeva G.; McKee, Edward E.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 10, 01.10.2015, p. 6328-6336.

Research output: Contribution to journalArticle

Snowdin, Jacob W. ; Hsiung, Chia Heng ; Kesterson, Daniel G. ; Kamath, Vasudeva G. ; McKee, Edward E. / Effects of zidovudine treatment on heart mRNA expression and mitochondrial DNA copy number associated with alterations in deoxynucleoside triphosphate composition in a neonatal rat model. In: Antimicrobial Agents and Chemotherapy. 2015 ; Vol. 59, No. 10. pp. 6328-6336.
@article{6fdbc71990f94fdb93f2ac55cc35ac57,
title = "Effects of zidovudine treatment on heart mRNA expression and mitochondrial DNA copy number associated with alterations in deoxynucleoside triphosphate composition in a neonatal rat model",
abstract = "The prevention of mother-to-child transmission (MTCT) of HIV is a crucial component in HIV therapy. Nucleoside reverse transcriptase inhibitors (NRTIs), primarily 3'-azido-3'-thymidine (AZT [zidovudine]), have been used to treat both mothers and neonates. While AZT is being replaced with less toxic drugs in treating mothers in MTCT prevention, it is still commonly used to treat neonates. Problems related to mitochondrial toxicity and potential mutagenesis associated with AZT treatment have been reported in treated cohorts. Yet little is known concerning the metabolism and potential toxicity of AZT on embryonic and neonatal tissues, especially considering that the enzymes of nucleoside metabolism change dramatically as many tissues convert from hyperplastic to hypertrophic growth during this period. AZT is known to inhibit thymidine phosphorylation and potentially alter deoxynucleoside triphosphate (dNTP) pools in adults. This study examines the effects of AZT on dNTP pools, mRNA expression of deoxynucleoside/deoxynucleotide metabolic enzymes, and mitochondrial DNA levels in a neonatal rat model. Results show that AZT treatment dramatically altered dNTP pools in the first 7 days of life after birth, which normalized to agematched controls in the second and third weeks. Additionally, AZT treatment dramatically increased the mRNA levels of many enzymes involved in deoxynucleotide synthesis and mitochondrial biogenesis during the first week of life, which normalized to age-matched controls by the third week. These results were correlated with depletion of mitochondrial DNA noted in the second week. Taken together, results demonstrated that AZT treatment has a powerful effect on the deoxynucleotide synthesis pathways that may be associated with toxicity and mutagenesis.",
author = "Snowdin, {Jacob W.} and Hsiung, {Chia Heng} and Kesterson, {Daniel G.} and Kamath, {Vasudeva G.} and McKee, {Edward E.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1128/AAC.01180-15",
language = "English (US)",
volume = "59",
pages = "6328--6336",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Effects of zidovudine treatment on heart mRNA expression and mitochondrial DNA copy number associated with alterations in deoxynucleoside triphosphate composition in a neonatal rat model

AU - Snowdin, Jacob W.

AU - Hsiung, Chia Heng

AU - Kesterson, Daniel G.

AU - Kamath, Vasudeva G.

AU - McKee, Edward E.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - The prevention of mother-to-child transmission (MTCT) of HIV is a crucial component in HIV therapy. Nucleoside reverse transcriptase inhibitors (NRTIs), primarily 3'-azido-3'-thymidine (AZT [zidovudine]), have been used to treat both mothers and neonates. While AZT is being replaced with less toxic drugs in treating mothers in MTCT prevention, it is still commonly used to treat neonates. Problems related to mitochondrial toxicity and potential mutagenesis associated with AZT treatment have been reported in treated cohorts. Yet little is known concerning the metabolism and potential toxicity of AZT on embryonic and neonatal tissues, especially considering that the enzymes of nucleoside metabolism change dramatically as many tissues convert from hyperplastic to hypertrophic growth during this period. AZT is known to inhibit thymidine phosphorylation and potentially alter deoxynucleoside triphosphate (dNTP) pools in adults. This study examines the effects of AZT on dNTP pools, mRNA expression of deoxynucleoside/deoxynucleotide metabolic enzymes, and mitochondrial DNA levels in a neonatal rat model. Results show that AZT treatment dramatically altered dNTP pools in the first 7 days of life after birth, which normalized to agematched controls in the second and third weeks. Additionally, AZT treatment dramatically increased the mRNA levels of many enzymes involved in deoxynucleotide synthesis and mitochondrial biogenesis during the first week of life, which normalized to age-matched controls by the third week. These results were correlated with depletion of mitochondrial DNA noted in the second week. Taken together, results demonstrated that AZT treatment has a powerful effect on the deoxynucleotide synthesis pathways that may be associated with toxicity and mutagenesis.

AB - The prevention of mother-to-child transmission (MTCT) of HIV is a crucial component in HIV therapy. Nucleoside reverse transcriptase inhibitors (NRTIs), primarily 3'-azido-3'-thymidine (AZT [zidovudine]), have been used to treat both mothers and neonates. While AZT is being replaced with less toxic drugs in treating mothers in MTCT prevention, it is still commonly used to treat neonates. Problems related to mitochondrial toxicity and potential mutagenesis associated with AZT treatment have been reported in treated cohorts. Yet little is known concerning the metabolism and potential toxicity of AZT on embryonic and neonatal tissues, especially considering that the enzymes of nucleoside metabolism change dramatically as many tissues convert from hyperplastic to hypertrophic growth during this period. AZT is known to inhibit thymidine phosphorylation and potentially alter deoxynucleoside triphosphate (dNTP) pools in adults. This study examines the effects of AZT on dNTP pools, mRNA expression of deoxynucleoside/deoxynucleotide metabolic enzymes, and mitochondrial DNA levels in a neonatal rat model. Results show that AZT treatment dramatically altered dNTP pools in the first 7 days of life after birth, which normalized to agematched controls in the second and third weeks. Additionally, AZT treatment dramatically increased the mRNA levels of many enzymes involved in deoxynucleotide synthesis and mitochondrial biogenesis during the first week of life, which normalized to age-matched controls by the third week. These results were correlated with depletion of mitochondrial DNA noted in the second week. Taken together, results demonstrated that AZT treatment has a powerful effect on the deoxynucleotide synthesis pathways that may be associated with toxicity and mutagenesis.

UR - http://www.scopus.com/inward/record.url?scp=84942891971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942891971&partnerID=8YFLogxK

U2 - 10.1128/AAC.01180-15

DO - 10.1128/AAC.01180-15

M3 - Article

VL - 59

SP - 6328

EP - 6336

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -